BCMA Lentivirus | 78714

BCMA Lentivirus | 78714 | Gentaur US, UK & Europe Disrtribition

Category: Immunotherapy/Lentivirus

Application: Generate a stable cell line expressing human BCMA with G418 selection and limiting dilution

Background: B-cell maturation antigen (BCMA, also known as CD269 or tumor necrosis factor receptor superfamily member 17, TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CAR T cells targeting BCMA have clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.

Description: The BCMA Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human BCMA (NM_ 001192) driven by a CMV promoter and a G418 selection marker (Figure 1). Figure 1: Schematic of the lenti-vector used to generate the BCMA Lentivirus

Product Type: Lentivirus

Shippement Condition: -80°C